Apollo Hospitals Enterprise Limited has announced the receipt of an observation letter from the BSE Limited (BSE) on December 24, 2025, concerning the proposed composite scheme of arrangement. This scheme involves the demerger of the Identified Business Undertaking of Apollo Hospitals Enterprise Limited into Resultant Company (Apollo Healthtech Limited), the amalgamation of Apollo Healthco Limited (Transferor Company I) with and into Resultant Company, and the amalgamation of Keimed Private Limited (Transferor Company 2) with and into Resultant Company. The scheme also includes the subsequent listing of equity shares of Resultant Company on NSE and BSE. This follows an earlier intimation on September 24, 2025, regarding the approval from the Competition Commission of India. The observation letter from BSE, dated December 24, 2025, is in relation to the Scheme under Regulation 37 of the Listing Regulations. A copy of this letter has been made available on the company's website. The scheme is still subject to necessary statutory and regulatory approvals, as well as the approval of shareholders and creditors of the involved companies. The company was previously informed about the board of directors' decision on June 30, 2025, approving this composite scheme of arrangement.